Handbook of Pharmacogenomics and Stratified Medicine is a comprehensive resource to understand this rapidly advancing field aiming to deliver the right drug at the right dose to the right patient at the right time. It is designed to provide a detailed, but accessible review of the entire field from basic principles to applications in various diseases. The chapters are written by international experts to allow readers from a wide variety of backgrounds, clinical and non-clinical (basic geneticists, pharmacologists, clinicians, trialists, industry personnel, ethicists) to understand the principles underpinning the progress in this area, the successes, failures and the challenges ahead. To be accessible to the widest range of readers, the clinical application section introduces the disease process, existing therapies, followed by pharmacogenomics and stratified medicine details.
Medicine is the cornerstone of modern therapeutics prescribed on the basis that its benefit should outweigh its risk. It is well known that people respond differently to medications and in many cases the risk-benefit ratio for a particular drug may be a gray area. The last decade has seen a revolution in genomics both in terms of technological innovation and discovering genetic markers associated with disease. In parallel there has been steady progress in trying to make medicines safer and tailored to the individual. This has occurred across the whole spectrum of medicine, some more than others. In addition there is burgeoning interest from the pharmaceutical industry to leverage pharmacogenomics for more effective and efficient clinical drug development.
- Provides clinical and non-clinical researchers with practical information normally beyond their usual areas of research or expertise
- Includes an basic principles section explaining concepts of basic genetics, genetic epidemiology, bioinformatics, pharmacokinetics and pharmacodynamics
- Covers newer technologies- next generation sequencing, proteomics, metabolomics
- Provides information on animal models, lymphoblastoid cell lines, stem cells
- Provides detailed chapters on a wide range of disease conditions, implementation and regulatory issues
- Includes chapters on the global implications of pharmacogenomics
Handbook of Pharmacogenomics and Stratified Medicine is a comprehensive resource to understand this rapidly advancing field aiming to deliver the right drug at the right dose to the right patient at the right time. It is designed to provide a detailed, but accessible review of the entire field from basic principles to applications in various diseases. The chapters are written by international experts to allow readers from a wide variety of backgrounds, clinical and non-clinical (basic geneticists, pharmacologists, clinicians, trialists, industry personnel, ethicists) to understand the principles underpinning the progress in this area, the successes, failures and the challenges ahead. To be accessible to the widest range of readers, the clinical application section introduces the disease process, existing therapies, followed by pharmacogenomics and stratified medicine details.Medicine is the cornerstone of modern therapeutics prescribed on the basis that its benefit should outweigh its risk. It is well known that people respond differently to medications and in many cases the risk-benefit ratio for a particular drug may be a gray area. The last decade has seen a revolution in genomics both in terms of technological innovation and discovering genetic markers associated with disease. In parallel there has been steady progress in trying to make medicines safer and tailored to the individual. This has occurred across the whole spectrum of medicine, some more than others. In addition there is burgeoning interest from the pharmaceutical industry to leverage pharmacogenomics for more effective and efficient clinical drug development. Provides clinical and non-clinical researchers with practical information normally beyond their usual areas of research or expertise Includes an basic principles section explaining concepts of basic genetics, genetic epidemiology, bioinformatics, pharmacokinetics and pharmacodynamics Covers newer technologies- next generation sequencing, proteomics, metabolomics Provides information on animal models, lymphoblastoid cell lines, stem cells Provides detailed chapters on a wide range of disease conditions, implementation and regulatory issues Includes chapters on the global implications of pharmacogenomics
Contributors
Numbers in parentheses indicate the pages on which the authors’ contributions begin.
Peter D. Adams (57), Institute of Cancer Sciences, University of Glasgow and Beatson Institute for Cancer Research, Glasgow, UK
Avid M. Afzal (259), Unilever Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, UK
A. Aghemo (857), A.M. and A. Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy
Amaya Albalat (147), School of Natural Sciences, University of Stirling, UK
Jahad Alghamdi (235), Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
Safaa Mohammed M. Alsanosi (341), BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK
Russ B. Altman (289), Department of Genetics, Department of Bioengineering, Stanford University, USA
H.R. Ashbee (877), Mycology Reference Centre, Department of Microbiology, Leeds Teaching Hospitals NHS Trust, UK
Julia M. Barbarino (289), Department of Genetics, Stanford University, USA
Raymond Barfield (929), Pediatric Quality of Life Program, Duke University, USA
Michael P. Barrett (899), Wellcome Trust Centre for Molecular Parasitology and Glasgow Polyomics, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
Andrew V. Biankin (807) Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, UK
The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, Australia
St Vincent’s Clinical School, Faculty of Medicine, University of NSW, Australia
Department of Surgery, Bankstown Hospital, Australia
South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Australia
Catriona Brown (779), Institute of Cardiovascular and Medical Sciences, Glasgow, UK
Karl Burgess (181) Glasgow Polyomics, University of Glasgow, UK
Institute of Infection, Immunity and Inflammation, University of Glasgow, UK
Pablo Cacabelos (563), Chair of Genomic Medicine, Camilo José Cela University, Madrid, Spain; EuroEspes Biomedical Research Center, Corunna, Spain
Ramón Cacabelos (563), Chair of Genomic Medicine, Camilo José Cela University, Madrid, Spain; EuroEspes Biomedical Research Center, Corunna, Spain
David K. Chang (807) Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, UK
The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, Australia
St Vincent’s Clinical School, Faculty of Medicine, University of NSW, Australia
Department of Surgery, Bankstown Hospital, Australia
South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Australia
Xiao-Ping Chen (997), Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, PR China
P. Clark (857), Department of Gastroenterology, Princess Alexandra Hospital and School of Medicine, University of Queensland, Australia
Aislinn Cooper (41), Medical Genetics, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
Ann K. Daly (497), Institute of Cellular Medicine, Newcastle University, UK
Collet Dandara (969), Department of Clinical Laboratory Science, University of Cape Town, South Africa
Tushar Dixit (815), Mersey Deanery, UK
Kieran F. Docherty (715), BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, UK
Amy S. Etheridge (111), Eshelman School of Pharmacy, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, USA
Chiara Fabbri (543), Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
Silvia Galora (509), Department of Experimental and Clinical Medicine, University of Florence, Atherothrombotic Diseases Center, Careggi Hospital, Italy
Silvana Gaudieri (437) School of Anatomy, Physiology and Human Biology, University of Western Australia, Australia
Institute for Immunology and Infectious Diseases, Murdoch University, Australia
M.H. Gilleece (877), Department of Haematology, St James’ Institute of Oncology, Leeds Teaching Hospitals NHS Trust, UK
Federica Giordani (899), Wellcome Trust Centre for Molecular Parasitology and Glasgow Polyomics, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
Betti Giusti (509), Department of Experimental and Clinical Medicine, University of Florence, Atherothrombotic Diseases Center, Careggi Hospital, Italy
Dylan M. Glubb (111), Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia
Yan Gong (747), Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, USA
Delyth Graham (73), BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK
Sean M. Grimmond (807) Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, UK
Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Australia
Umamaheswaran Gurusamy (1035), Pharmacogenomics Laboratory, Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, India
Julia Hasler (969), African Institute of Biomedical Science and Technology, Zimbabwe
Yi-Jing He (997), Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, PR China
Pawel Herzyk (125), Glasgow Polyomics and The Institute of Molecular Cell and Systems Biology, University of Glasgow, UK
Chi Dang Hornik (929), Neonatal Intensive Care, Duke Children’s Hospital & Health Center, Duke University Medical Center, USA
Holger Husi (147), BHF Glasgow Cardiovascular Research Centre, ICAMS University of Glasgow, UK
Mara Helena Hutz (1013), Department of Genetics, Universidade Federal do Rio Grande do Sul, Brazil
Federico Innocenti (111) Eshelman School of Pharmacy, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, USA
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, USA
School of Medicine, University of North Carolina at Chapel Hill, USA
Akihiro Ishiguro (949), PMDA Omics Project, Pharmaceuticals & Medical Devices Agency (PMDA), Japan
Nigel B. Jamieson (807) Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, UK,
Academic Unit of Surgery, Faculty of Medicine, Glasgow Royal Infirmary, University of Glasgow, UK
Jae-Pil Jeon (89), Division of Brain Diseases, Center for Biomedical Science, Korea National Institute of Health, Korea Centers for Disease Control and Prevention, Republic of Korea
Julie A. Johnson (747) Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, USA
Department of Medicine, University of Florida, USA
Teri E. Klein (289), Department of Genetics, Stanford University, USA
David P. Leader (259), School of Life Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
Stefanie Lip (365), BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK
Zhao-Qian Liu (997), Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, PR China
Komal Loya (207), College of Medical Veterinary and Life Sciences, Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK
Vangelis G. Manolopoulos (683), Laboratory of Pharmacology and Clinical Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
Rossella Marcucci (509), Department of Experimental and Clinical Medicine, University of Florence, Atherothrombotic Diseases Center, Careggi Hospital, Italy
Collen Masimirembwa (969), African Institute of Biomedical Science and Technology, Zimbabwe
Yoshihiko Matsumoto (543), Department of Psychiatry, School of Medicine, Yamagata University, Japan
Tony McBryan (57), Institute of Cancer Sciences, University of Glasgow and Beatson Institute for Cancer Research, Glasgow, UK
Linsay...
| Erscheint lt. Verlag | 28.4.2014 |
|---|---|
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik | |
| Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
| ISBN-10 | 0-12-386883-1 / 0123868831 |
| ISBN-13 | 978-0-12-386883-1 / 9780123868831 |
| Haben Sie eine Frage zum Produkt? |
PDF (Adobe DRM)Größe: 82,8 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
EPUB (Adobe DRM)Größe: 35,9 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
